Cancer is a complex and refractory disease, which can disseminate from primary site to a different site even at an early stage. Cancer immunotherapy harnesses host immune system to battle against cancer, but only a minority of patients benefit from it. Genetic-based technologies have significantly promoted the development of cancer immunotherapy. Here we describe genetic-based cancer immunotherapies in three aspects: recombinant cancer vaccine, immune checkpoint blockade therapy and adoptive cell transfer. In the future, multi-disciplinary collaboration will greatly increase the scope and effectiveness of cancer immunotherpy.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81401840]; Sun Yatsen University Starting Funds for Young Teachers [16ykpy31]; Technology Project of Huangpu District Guangzhou City [201611]
第一作者机构：[1]the First Affiliated Hospital, Sun Yat-sen University
共同第一作者：
通讯作者：
通讯机构：[1]the First Affiliated Hospital, Sun Yat-sen University[*1]Department of Orthopaedic Surgery, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Second Road, Guangzhou, P.R. China 510080
推荐引用方式(GB/T 7714)：
Wang Xiaobo,Fan Shaoyi,Pan Hehai,et al.Cancer immunotherapy for metastasis: past, present and future[J].BRIEFINGS IN FUNCTIONAL GENOMICS.2019,18(2):140-146.doi:10.1093/bfgp/ely022.
APA：
Wang, Xiaobo,Fan, Shaoyi,Pan, Hehai,Chen, Wenli&Wang, Hua.(2019).Cancer immunotherapy for metastasis: past, present and future.BRIEFINGS IN FUNCTIONAL GENOMICS,18,(2)
MLA：
Wang, Xiaobo,et al."Cancer immunotherapy for metastasis: past, present and future".BRIEFINGS IN FUNCTIONAL GENOMICS 18..2(2019):140-146
：